The vaccines are developed up to proof of concept and licensed to partners for further development and commercialization. The company’s proprietary vaccine adjuvant technology Endocine™, which is a key element of the nasal vaccines, is also offered to license partners for development in various indications.
Eurocine Vaccines AB
Eurocine Vaccines is a publicly listed, clinical-stage company developing nasal vaccines that meet important medical needs.